Antineoplastic Combined Chemotherapy Protocols
"Antineoplastic Combined Chemotherapy Protocols" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
| Descriptor ID |
D000971
|
| MeSH Number(s) |
E02.183.750.500 E02.319.077.500 E02.319.310.037
|
| Concept/Terms |
Antineoplastic Combined Chemotherapy Protocols- Antineoplastic Combined Chemotherapy Protocols
- Combined Antineoplastic Agents
- Antineoplastic Agents, Combined
- Agent, Combined Antineoplastic
- Agents, Combined Antineoplastic
- Antineoplastic Agent, Combined
- Combined Antineoplastic Agent
- Antineoplastic Combined Chemotherapy Regimens
- Drug Combinations, Antineoplastic
- Anticancer Drug Combinations
- Anticancer Drug Combination
- Drug Combination, Anticancer
- Drug Combinations, Anticancer
- Antineoplastic Drug Combinations
- Antineoplastic Drug Combination
- Combinations, Antineoplastic Drug
- Drug Combination, Antineoplastic
Antineoplastic Chemotherapy Protocols- Antineoplastic Chemotherapy Protocols
- Antineoplastic Chemotherapy Protocol
- Chemotherapy Protocol, Antineoplastic
- Protocol, Antineoplastic Chemotherapy
- Protocols, Antineoplastic Chemotherapy
- Cancer Chemotherapy Protocols
- Cancer Chemotherapy Protocol
- Chemotherapy Protocol, Cancer
- Chemotherapy Protocols, Cancer
- Protocol, Cancer Chemotherapy
- Protocols, Cancer Chemotherapy
- Chemotherapy Protocols, Antineoplastic
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Combined Chemotherapy Protocols".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Combined Chemotherapy Protocols".
This graph shows the total number of publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in this website by year, and whether "Antineoplastic Combined Chemotherapy Protocols" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 3 | 0 | 3 |
| 2000 | 1 | 0 | 1 |
| 2002 | 2 | 0 | 2 |
| 2003 | 3 | 1 | 4 |
| 2004 | 3 | 1 | 4 |
| 2005 | 4 | 3 | 7 |
| 2006 | 9 | 2 | 11 |
| 2007 | 8 | 2 | 10 |
| 2008 | 16 | 1 | 17 |
| 2009 | 10 | 3 | 13 |
| 2010 | 10 | 1 | 11 |
| 2011 | 13 | 5 | 18 |
| 2012 | 9 | 3 | 12 |
| 2013 | 10 | 1 | 11 |
| 2014 | 13 | 0 | 13 |
| 2015 | 13 | 5 | 18 |
| 2016 | 9 | 3 | 12 |
| 2017 | 19 | 4 | 23 |
| 2018 | 10 | 6 | 16 |
| 2019 | 21 | 3 | 24 |
| 2020 | 18 | 9 | 27 |
| 2021 | 11 | 11 | 22 |
| 2022 | 4 | 10 | 14 |
| 2023 | 3 | 3 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in Profiles.
-
The MUC1-HIF-1a signaling axis regulates pancreatic cancer pathogenesis through polyamine metabolism remodeling. Proc Natl Acad Sci U S A. 2024 Apr 02; 121(14):e2315509121.
-
Management of limited-stage Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2023 Dec 08; 2023(1):500-509.
-
Surgical management of peritoneal metastasis: Opportunities for pharmaceutical research. J Control Release. 2023 09; 361:717-726.
-
Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemia. J Geriatr Oncol. 2023 Jul; 14(6):101538.
-
Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance: A Narrative Review. JAMA Oncol. 2023 Jun 01; 9(6):851-859.
-
Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies. Clin Lymphoma Myeloma Leuk. 2023 09; 23(9):674-686.
-
Combination therapies for cancer: challenges and opportunities. BMC Med. 2023 05 04; 21(1):171.
-
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. N Engl J Med. 2023 Jun 08; 388(23):2159-2170.
-
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. N Engl J Med. 2023 Jun 08; 388(23):2145-2158.
-
NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma. J Clin Oncol. 2023 02 20; 41(6):1285-1295.